QSOA Stock Overview
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Surface Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.99 |
| 52 Week High | US$1.41 |
| 52 Week Low | US$0.52 |
| Beta | 1.75 |
| 11 Month Change | 16.19% |
| 3 Month Change | 36.16% |
| 1 Year Change | -27.10% |
| 33 Year Change | -82.41% |
| 5 Year Change | -88.77% |
| Change since IPO | -90.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| QSOA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.7% | 0.8% | 0.8% |
| 1Y | -27.1% | -18.3% | 8.6% |
Return vs Industry: QSOA underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: QSOA underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| QSOA volatility | |
|---|---|
| QSOA Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: QSOA's share price has been volatile over the past 3 months.
Volatility Over Time: QSOA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 35 | Rob Ross | www.surfaceoncology.com |
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No.
Surface Oncology, Inc. Fundamentals Summary
| QSOA fundamental statistics | |
|---|---|
| Market cap | €60.83m |
| Earnings (TTM) | -€86.46m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs QSOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QSOA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$67.00m |
| Gross Profit | -US$67.00m |
| Other Expenses | US$25.50m |
| Earnings | -US$92.50m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did QSOA perform over the long term?
See historical performance and comparison